Conference Coverage (12th World AIDS)

Hypertension May Limit New AIDS Therapy Approach

Published in Hepatitis Weekly, September 7th, 1998

New strategies to block HIV infection may have untoward side effects.

Such strategies would block or down-regulate the CCR5 chemokine receptor needed for macrophage-tropic (M-tropic) HIV-1 strains to infect cells. M-tropic strains are responsible for the vast majority of HIV infections.

People homozygous for a naturally occurring mutation that inactivates the CCR5 receptor resist HIV infection and appear healthy. Researchers are thus seeking a drug or immune therapy that would reproduce this condition. But a new study shows that people with the CCR5-delta32/delta32 mutation are at increased risk of hypertension, and that they appear to have...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry